JP2023521436A - Ｔ細胞細胞傷害性の調節および関連療法 - Google Patents

Ｔ細胞細胞傷害性の調節および関連療法 Download PDF

Info

Publication number
JP2023521436A
JP2023521436A JP2022562684A JP2022562684A JP2023521436A JP 2023521436 A JP2023521436 A JP 2023521436A JP 2022562684 A JP2022562684 A JP 2022562684A JP 2022562684 A JP2022562684 A JP 2022562684A JP 2023521436 A JP2023521436 A JP 2023521436A
Authority
JP
Japan
Prior art keywords
cells
cell
engineered
tumor
sirpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521436A5 (enExample
Inventor
ケサダ，セルジオ
ペグス，カール
スワントン，チャールズ
ゴラニ，イーサン
リーディング，ジェームズ
ガルベス－カンチーノ，フェリペ
カラジャンニ，デスポイナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2023521436A publication Critical patent/JP2023521436A/ja
Publication of JP2023521436A5 publication Critical patent/JP2023521436A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
JP2022562684A 2020-04-17 2021-04-16 Ｔ細胞細胞傷害性の調節および関連療法 Pending JP2023521436A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2005599.2A GB202005599D0 (en) 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy
GB2005599.2 2020-04-17
PCT/EP2021/059989 WO2021209627A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy

Publications (2)

Publication Number Publication Date
JP2023521436A true JP2023521436A (ja) 2023-05-24
JP2023521436A5 JP2023521436A5 (enExample) 2024-04-26

Family

ID=70859980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562684A Pending JP2023521436A (ja) 2020-04-17 2021-04-16 Ｔ細胞細胞傷害性の調節および関連療法

Country Status (12)

Country Link
US (1) US20230158073A1 (enExample)
EP (1) EP4135725A1 (enExample)
JP (1) JP2023521436A (enExample)
KR (1) KR20230004643A (enExample)
CN (1) CN115697357A (enExample)
AU (1) AU2021255917A1 (enExample)
BR (1) BR112022020819A2 (enExample)
CA (1) CA3175622A1 (enExample)
GB (1) GB202005599D0 (enExample)
IL (1) IL297309A (enExample)
MX (1) MX2022012924A (enExample)
WO (1) WO2021209627A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
WO2025063257A1 (ja) * 2023-09-22 2025-03-27 国立大学法人大阪大学 制御性ｔ細胞を製造する方法
GB202417285D0 (en) * 2024-11-25 2025-01-08 Univ Oxford Innovation Ltd Expanded t cell population

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231871A1 (en) * 2017-06-12 2018-12-20 Emory University T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
JP2019524156A (ja) * 2016-08-03 2019-09-05 ジョン・エフ・ディパージオＪｏｈｎ Ｆ． ＤＩＰＥＲＳＩＯ キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ−ｔ細胞の遺伝子編集

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2015330898B2 (en) * 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
CA2977106A1 (en) * 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
EP3606518A4 (en) * 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
US12226479B2 (en) * 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524156A (ja) * 2016-08-03 2019-09-05 ジョン・エフ・ディパージオＪｏｈｎ Ｆ． ＤＩＰＥＲＳＩＯ キメラ抗原受容体でのｔ細胞性悪性腫瘍の治療のためのｃａｒ−ｔ細胞の遺伝子編集
WO2018231871A1 (en) * 2017-06-12 2018-12-20 Emory University T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. GYORFFY ET AL.: "The impact of CRISPR-Cas9 mediated editing of the stomatin gene on erythroid differentiation", TRANSFUSION MEDICINE, vol. Vol.29, Supplement 2, JPN6025017818, 2019, pages 35 - 31, ISSN: 0005743251 *

Also Published As

Publication number Publication date
IL297309A (en) 2022-12-01
WO2021209627A1 (en) 2021-10-21
US20230158073A1 (en) 2023-05-25
BR112022020819A2 (pt) 2022-11-29
MX2022012924A (es) 2023-04-03
CA3175622A1 (en) 2021-10-21
CN115697357A (zh) 2023-02-03
AU2021255917A1 (en) 2022-11-17
KR20230004643A (ko) 2023-01-06
EP4135725A1 (en) 2023-02-22
GB202005599D0 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
AU2022203507B2 (en) Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
US20230203124A1 (en) Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
Zacharakis et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
KR102809909B1 (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
JP6815992B2 (ja) キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
KR20230004643A (ko) T 세포 세포독성의 조정 및 관련 요법
JP2025134822A (ja) Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
BR112021016340A2 (pt) Métodos para produzir células t autólogas úteis para tratar câncer e composições das mesmas
CA2963364A1 (en) Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
JP2020523018A (ja) がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
EP3622092A2 (en) Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
US20240091259A1 (en) Generation of anti-tumor t cells
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
WO2022272245A2 (en) Unique cancer associated fibroblast subsets predict response to immunotherapy
Lennerz et al. T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H
US20210290672A1 (en) Regulation of tumor-associated t cells
US20250041344A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
CA3220820A1 (en) Methods of treating cancer with cd-40 agonists
US20250236915A1 (en) Cd4+ t cell markers, compositions, and methods for cancer
JP2026516201A (ja) 急性骨髄性白血病（ａｍｌ）の標的化免疫療法のための方法
Gray et al. Agnieszka Goral1, Malgorzata Firczuk1, Klaudyna Fidyt1, Marta Sledz1, Francesca Simoncello2, Karolina Siudakowska1, Giulia Pagano3, Etienne Moussay3, Jeroˆme Paggetti3, Patrycja Nowakowska1, Stefania Gobessi4, Joanna Barankiewicz5, Aleksander Salomon-Perzynski5, Federica Benvenuti2, Dimitar G. Efremov4, Przemyslaw Juszczynski5, Ewa Lech-Maranda5 and Angelika Muchowicz1
Sugimura Generation of functional macrophages from human embryonic organoids
Hall Utilizing Neoantigen-Specific CD4+ T Cells and Immune Checkpoint Modulation to Advance Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Patients
EP4698661A1 (en) Tumor specific gamma delta t cells
WO2025106420A2 (en) Disruption of ets1 and rbpj in t cells to enhance immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202